bioAffinity Technologies (NASDAQ:BIAF – Get Free Report) is one of 39 public companies in the “Commercial physical research” industry, but how does it compare to its competitors? We will compare bioAffinity Technologies to related businesses based on the strength of its analyst recommendations, dividends, profitability, valuation, earnings, institutional ownership and risk.
Earnings and Valuation
This table compares bioAffinity Technologies and its competitors revenue, earnings per share and valuation.
Gross Revenue | Net Income | Price/Earnings Ratio | |
bioAffinity Technologies | $2.53 million | -$7.94 million | -2.88 |
bioAffinity Technologies Competitors | $1.55 billion | $101.44 million | 0.11 |
bioAffinity Technologies’ competitors have higher revenue and earnings than bioAffinity Technologies. bioAffinity Technologies is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Insider and Institutional Ownership
Profitability
This table compares bioAffinity Technologies and its competitors’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
bioAffinity Technologies | -313.34% | -107.20% | -84.10% |
bioAffinity Technologies Competitors | -249.68% | -18.81% | -11.37% |
Volatility & Risk
bioAffinity Technologies has a beta of 3.93, meaning that its stock price is 293% more volatile than the S&P 500. Comparatively, bioAffinity Technologies’ competitors have a beta of 5.57, meaning that their average stock price is 457% more volatile than the S&P 500.
Analyst Recommendations
This is a summary of current ratings for bioAffinity Technologies and its competitors, as provided by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
bioAffinity Technologies | 0 | 0 | 0 | 0 | N/A |
bioAffinity Technologies Competitors | 50 | 817 | 1300 | 31 | 2.60 |
As a group, “Commercial physical research” companies have a potential upside of 7.06%. Given bioAffinity Technologies’ competitors higher probable upside, analysts clearly believe bioAffinity Technologies has less favorable growth aspects than its competitors.
Summary
bioAffinity Technologies competitors beat bioAffinity Technologies on 9 of the 10 factors compared.
About bioAffinity Technologies
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas.
Receive News & Ratings for bioAffinity Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bioAffinity Technologies and related companies with MarketBeat.com's FREE daily email newsletter.